Art-175 Is a Highly Efficient Antibacterial against Multidrug-Resistant Strains and Persisters of Pseudomonas aeruginosa

@article{Briers2014Art175IA,
  title={Art-175 Is a Highly Efficient Antibacterial against Multidrug-Resistant Strains and Persisters of Pseudomonas aeruginosa},
  author={Y. Briers and M. Walmagh and B. Grymonprez and M. Biebl and J. Pirnay and Valerie Defraine and J. Michiels and William Cenens and A. Aertsen and Stefan Miller and R. Lavigne},
  journal={Antimicrobial Agents and Chemotherapy},
  year={2014},
  volume={58},
  pages={3774 - 3784}
}
ABSTRACT Artilysins constitute a novel class of efficient enzyme-based antibacterials. Specifically, they covalently combine a bacteriophage-encoded endolysin, which degrades the peptidoglycan, with a targeting peptide that transports the endolysin through the outer membrane of Gram-negative bacteria. Art-085, as well as Art-175, its optimized homolog with increased thermostability, are each composed of the sheep myeloid 29-amino acid (SMAP-29) peptide fused to the KZ144 endolysin. In contrast… Expand
Efficacy of Artilysin Art-175 against Resistant and Persistent Acinetobacter baumannii
TLDR
It is reported that Art-175 is highly bactericidal against stationary-phase cells of multidrug-resistant Acinetobacter baumannii, even resulting in a complete elimination of large inocula, and represents a highly active Artilysin against two of the most life-threatening pathogens of the order Pseudomonadales. Expand
Artilysins are a novel class of enzyme-based antibacterials that quickly kill (multidrug-resistant) Pseudomonas aeruginosa and their persisters: from concept to application.
TLDR
Artilysins have a completely novel mode-of-action, are highly bactericidal within a few minutes, irrespective of the presence of drug resistance mechanisms, show a low probability of resistance development, and have unprecedented bactericidal activity against persisters. Expand
Antibacterial Activity of a Novel Peptide-Modified Lysin Against Acinetobacter baumannii and Pseudomonas aeruginosa
TLDR
A novel peptide-modified lysin with significant antibacterial activity against both logarithmic and stationary phase A. baumannii and P. aeruginosa cells in buffer is reported, but further optimization is needed to achieve broad activity in diverse bio-matrices. Expand
Breaking barriers: expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria.
TLDR
This review reports on the most recent advances in the development of endolysins to kill Gram-negative species with a special focus on endolysin-engineered Artilysins(®). Expand
A Novel Antimicrobial Endolysin, LysPA26, against Pseudomonas aeruginosa
TLDR
Results show that LysPA26 is a new and promising antimicrobial agent for the combat of Gram-negative pathogens. Expand
‘Artilysation’ of endolysin λSa2lys strongly improves its enzymatic and antibacterial activity against streptococci
TLDR
Art-240, a chimeric protein of the anti-streptococcal endolysin λSa2lys and the polycationic peptide PCNP, shows a similar species specificity as the parents, but the bactericidal activity against streptococci increases and is less affected by elevated NaCl concentrations and pH variations. Expand
From endolysins to Artilysin®s: novel enzyme-based approaches to kill drug-resistant bacteria.
TLDR
The present review summarizes and discusses the potential applications of endolysins as new anti-microbials and their selective activity against both Gram-positive and Gram-negative pathogens and mycobacteria, and the limited resistance development reported so far. Expand
Structural and Enzymatic Characterization of ABgp46, a Novel Phage Endolysin with Broad Anti-Gram-Negative Bacterial Activity
TLDR
This globular endolysin exhibits a broad and high activity against Gram-negative pathogens, that can be enhanced in presence of citric and malic acid, and be used in human and veterinary medicine. Expand
Bacteriophage-derived Endolysins to Target Gram-Negative Bacteria.
TLDR
While lysins demonstrates clear potential in managing bacterial infections caused by the drug-resistant G-ve bacteria, there are still challenges hindering their translation into clinical settings, including safety issues with OMP use, low efficiency against stationary phase bacteria and problems in stability. Expand
Antimicrobial bacteriophage-derived proteins and therapeutic applications
TLDR
The current preclinical state of using phage-derived endolysins, virion-associated peptidoglycan hydrolases, polysaccharide depolymerases, and holins for the treatment of bacterial infection is reviewed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 56 REFERENCES
Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides
TLDR
Virolysins are the most promising candidates as they are highly specific and have the capability to rapidly lyse antibiotic‐resistant bacteria on a generally species‐specific basis. Expand
Lysins: the arrival of pathogen-directed anti-infectives.
TLDR
Lysins are bacterial cell-wall hydrolytic enzymes that selectively and rapidly kill specific Gram-positive bacteria providing a targeted therapeutic approach with minimal impact on unrelated commensal flora. Expand
Structural engineering of a phage lysin that targets Gram-negative pathogens
TLDR
This work solved the crystal structures of a Yersinia pestis outer membrane transporter called FyuA and a bacterial toxin called pesticin that targets this transporter and designs a phage therapy reagent comprised of the F RyuA binding domain of pesticin fused to the N-terminus of T4 lysozyme. Expand
Combating multidrug-resistant Gram-negative bacterial infections
TLDR
This review provides an overview of recent R&D activities in the search for novel antibiotics against MDR Gram-negatives and examines new analogs of existing antibiotic molecules as well as agents against novel bacterial targets such as aminoacyl–tRNA synthetase and peptide deformylase. Expand
Control of Bacterial Persister Cells by Trp/Arg-Containing Antimicrobial Peptides
TLDR
It is reported that cationic membrane-penetrating peptides containing various numbers of arginine and tryptophan repeats are effective in killing persister cells of Escherichia coli HM22, a hyper-persister producer. Expand
Combination Therapy With Lysin CF-301 and Antibiotic Is Superior to Antibiotic Alone for Treating Methicillin-Resistant Staphylococcus aureus–Induced Murine Bacteremia
TLDR
Lysin CF-301 demonstrates activity on drug-resistant strains, has a low resistance profile, eradicates biofilms, and acts synergistically with antibiotics, and represents an attractive alternative to antibiotic monotherapies currently used to treat S. aureus bacteremia. Expand
Metabolite-Enabled Eradication of Bacterial Persisters by Aminoglycosides
TLDR
It is shown that specific metabolic stimuli enable the killing of both Gram-negative and Gram-positive bacterial persisters with aminoglycosides, and this approach can improve the treatment of chronic infections in a mouse urinary tract infection model. Expand
Bacteriophage endolysins as novel antimicrobials.
TLDR
The modular structure of endolysins is reviewed, in which cell wall binding and catalytic functions are separated, as well as their mechanism of action, lytic activity and potential as antimicrobials. Expand
Muralytic activity and modular structure of the endolysins of Pseudomonas aeruginosa bacteriophages φKZ and EL
TLDR
Both KZ144 and EL188 appear to be a natural chimeric enzyme, originating from a recombination of a cell wall‐binding domain encoded by a Bacillus or Clostridium species and a catalytic domain of an unknown ancestor. Expand
A Novel Chimeric Lysin Shows Superiority to Mupirocin for Skin Decolonization of Methicillin-Resistant and -Sensitive Staphylococcus aureus Strains
TLDR
The potential of developing ClyS as a novel class of topical antimicrobial agents specific to staphylococcus is demonstrated, with a decreased potential for the development of resistance by MRSA and MSSA organisms compared to that from the use of mupirocin in vitro. Expand
...
1
2
3
4
5
...